Form 4: BioCryst CEO's Tax-Related Stock Transaction Reported
Insider Transaction Report
BioCryst Pharmaceuticals CEO Jon P. Stonehouse reported a tax-related stock transaction involving the withholding of shares to cover vesting restricted stock units.
Summary
- Jon P. Stonehouse, Chief Executive Officer and Director of BioCryst Pharmaceuticals Inc. (BCRX), reported a transaction on December 12, 2025.
- The transaction involved the withholding of 27,368 shares of Common Stock by the Issuer at a price of $7.57 per share.
- This withholding was to satisfy required tax obligations in connection with the vesting of previously granted restricted stock units.
- The filing explicitly states this transaction does not represent a sale by the reporting person.
- Following the transaction, Mr. Stonehouse directly beneficially owns 1,405,222 shares of Common Stock.
- Additionally, his wife indirectly beneficially owns 30,000 shares as co-trustee of the Caroline Stonehouse Irrevocable Trust and another 30,000 shares as co-trustee of the Samuel Stonehouse Irrevocable Trust.
Sentiment
Score: 5
Explanation: The filing reports a routine tax-related transaction for RSU vesting, which is a neutral event and not indicative of management's sentiment towards the company's future performance.
Positives
- The transaction is a routine tax withholding and does not represent a voluntary sale of shares by the CEO, indicating no change in his direct investment posture.
Future Outlook
NA
Industry Context
NA
Key Dates
| Date | Description |
|---|---|
| 12/12/2025 | Date of earliest transaction, involving shares withheld for tax obligations related to RSU vesting. |
| 12/16/2025 | Signature date of the reporting person's power of attorney. |
Recommendation
holdThis Form 4 filing details a routine tax-related transaction where shares were withheld to cover obligations from restricted stock unit vesting. It does not represent a sale by the insider and therefore provides no new fundamental information to alter an investment thesis. The transaction is a standard part of executive compensation and does not signal any change in the company's outlook or the insider's confidence. Investors should hold their position based on existing fundamental analysis rather than this neutral event.
Keywords
BioCryst Pharmaceuticals, BCRX, Form 4, Insider Transaction, Stock Withholding, CEO, Restricted Stock Units, RSU
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.